cytochrome

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/22

encourage image

There's no tags or description

Looks like no tags are added yet.

23 Terms

1
New cards

Cytochrome P450 hydroxylation mechanism

CYP enzymes inset 1 atom of molecule O2 into RH substrate = hydroxylated product (ROH), while other O2 atom is reduced to H2O (hydrophobic → hydrophilic)

  1. Substrate (drug RH) binds to CYP haem iron (Fe3+) in enzyme’s active site = conformational change

  2. Fe3+ reduced to Fe2+ via NADPH dependent reductase, allowing O2 to bind

  3. O2 binds to Fe2+ - substrate complex

  4. Second electron reduction and protonation (H+) cleaves O-O bond → releasing H2O and forms highly reactive iron-oxo species (Compound I/ FeO3+)

  5. Compound I abstracts a H atom from substrate and inserts an OH group → hydroxylated product (more polar = increases drug solubility for Phase II)

  6. Hydroxylated drug released and restores Fe3+ resting enzyme state


2
New cards

CYP roles

Convert lipophilic compounds (xenobiotics) into more polar molecules, facilitating subsequent Phase II conjugation and excretion

Hormone metabolism

CYP-mediated metabolism in bioactivation, generating reactive intermediates that may be carcinogenic (procarcinogens → highly reactive electrophilic carcinogenic products)

3
New cards

1* allele

Reference or wild type with normal function

4
New cards

2* or 3*

Enzyme doesn’t work properly → reduced or absent enzyme activity = loss of function = decreased drug metabolism

5
New cards

17*

Increased enzyme activity (gain of function)

6
New cards

Star alleles significance

Used to classify genetic variants of drug-metabolising enzymes, particularly CYP enzymes

7
New cards

CYP enzymes roles

Metabolise xenobiotics - foreign compounds not essential for homeostasis

Bioactivation - generating reactive intermediates that may be carcinogenic (procarcinogens → highly reactive electrophilic carcinogenic products)

Facilitate Phase II conjugation and excretion

8
New cards

How is CYP enzymes highly varaible?

Due to genetic polymorphisms and environmental influences = a major determinant of interindividual variability in drug response

9
New cards

What do genetic polymorphisms and variability in CYP enzymes do?

Significantly impact enzyme activity and are a major cause of variable drug response → influences drug metabolism and therapeutic outcomes

10
New cards

Genetic variants

Single nucleotide polymorphisms (SNPs)

Genetic deletions

Copy number variants (CNVs)

11
New cards

What do genetic variants do?

Alter enzyme structure or expression → phenotypes ranging from poor to ultra rapid metabolisers

12
New cards

Poor metabolisers

Have little or no enzyme activity

Resulting from combinations of “no function” alleles

Often necessitates dosage adjustment, avoiding excess bioavailability

Increased drug levels and toxicity

13
New cards

Intermediate metabolisers

Enzyme activity reduced → variable response

14
New cards

Extensive metabolisers

Normal enzyme activity → expected response

15
New cards

Ultra-rapid metabolisers

Very high enzyme activity due to gene duplication → decreased / subtherapeutic drug levels (breaks down drug quickly) → treatment failure

16
New cards

Why is variability important?

Important for drugs with narrow therapeutic indices and for prodrugs requiring metabolic activation

Guides personalised drug therapy

17
New cards

Phenotypic nomenclature

Describes how genetic variation in drug metabolising enzymes (CYP) translates into observable metabolic capacity - translates an individuals genetic makeup into observable metabolic capacities

Allows clinicians to predict how a patient will process medications

18
New cards

How does phenotypic nomenclature work?

Based on individuals phenotype, composed of alleles inherited from each parent, forms haplotypes and diplotypes which determine enzyme activity levels

Based on this, patients are classified into phenotypes: poor, intermediate, extensive or ultra rapid metabolisers

19
New cards

Star allele system significance

Used to classify genetic variants (specific haplotypes) of drug metabolising enzymes (CYP) that influence drug metabolism

20
New cards

Phase II metabolism

Detoxification process involving conjugation reactions with enzymes (UGTS, SULTS, etc) that attach large endogenous polar groups (glucuronic acid or sulfate) to drugs or Phase I metabolites

Increase water excretion and facilitate excretion

Generally produce inactive, non-toxic metabolites

21
New cards

Key enzymes in Phase II

UGTs - UDP- Glucuronosyltransferases

SULTs - sulfotransferases

GSTs - glutathione S-transferases

22
New cards

Phase III function

Use membrane transport proteins to facilitate movement and actively pump water soluble metabolites from kidneys, liver and intestines into bile, urine or intestinal lumen for excretion

Final conjugates rate eliminated primarily in kidneys (urine) and liver (bile → faeces)

23
New cards

2 transporters in phase iii

ATP-binding cassette (ABC) transporters - use energy from ATP hydrolysis to actively transport substrates against their concetration gradients (energy dependent) - over expression of abc transporters in tumour cells is main mechanism of tumour multidrug resistance (TMR)

Solute carrier (SLC) transporters - use membrane-bound proteins which rely on existing ion gradients to transport intracellular nutrients and metabolites = influences activity and potency of cytotoxic drugs